tiprankstipranks
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
US Market

Allarity Therapeutics, Inc. (ALLR) Stock Price & Analysis

57 Followers

ALLR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.30 - $154.40
Previous Close$0.31
Volume187.93K
Average Volume (3M)126.66K
Market Cap
$1.90M
Enterprise Value$1.70M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$1.17M
Price to Earnings (P/E)>-0.1
Beta1.20
May 24, 2024
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-206.45
Shares Outstanding6,178,892
10 Day Avg. Volume140,922
30 Day Avg. Volume126,659
Standard Deviation0.34
R-Squared0.00162
Alpha-0.30
Financial Highlights & Ratios
Price to Book (P/B)-0.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.95
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

0.00%0.09%10.46%89.46%
0.00%
Insiders
10.46% Other Institutional Investors
89.46% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

ALLR FAQ

What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.30 and its highest was $154.40 in the past 12 months.
    What is Allarity Therapeutics, Inc.’s market cap?
    Currently, no data Available
    When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
    Allarity Therapeutics, Inc.’s upcoming earnings report date is May 24, 2024 which is in 57 days.
      How were Allarity Therapeutics, Inc.’s earnings last quarter?
      Allarity Therapeutics, Inc. released its earnings results on Mar 08, 2024. The company reported $195.33 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $195.58.
        Is Allarity Therapeutics, Inc. overvalued?
        According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Allarity Therapeutics, Inc. pay dividends?
          Allarity Therapeutics, Inc. does not currently pay dividends.
          What is Allarity Therapeutics, Inc.’s EPS estimate?
          Allarity Therapeutics, Inc.’s EPS estimate is -$0.53.
            How many shares outstanding does Allarity Therapeutics, Inc. have?
            Allarity Therapeutics, Inc. has 6,178,892 shares outstanding.
              What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
              Allarity Therapeutics, Inc. reported an EPS of $195.33 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
                Currently, no hedge funds are holding shares in ALLR
                ---

                Allarity Therapeutics, Inc. Stock Smart Score

                Company Description

                Allarity Therapeutics, Inc.

                Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Aptose Biosciences
                Bio-Path Holdings
                Marinus
                Protalix
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis